A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia.

Objective: Olanzapine and other antipsychotics are not approved by the U.S. Food and Drug Administration to treat behavioral disturbances associated with dementia, but they are often prescribed to these patients.